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Leprosy, a contagious and chronic granulomatous disease caused by Mycobacterium leprae, is classically
known to have cutaneous and neurologic sequelae. Leprosy usually has a long incubation period and may
manifest with a variety of autoimmune phenomena reminiscent of autoimmune diseases, such as sys-
temic lupus erythematosus (SLE) or rheumatoid arthritis. We describe a case of a 40-year-old man
presenting with a long history of recurrent skin rashes and hand numbness, initially diagnosed as carpal
tunnel syndrome and SLE, who was later proven to have borderline leprosy. This suggests that this
underappreciated disease should still be considered in the differential diagnosis of granulomatous skin
rashes with rheumatic manifestations, even in nonendemic regions.
Copyright  2013, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Leprosy, also known as Hansen’s disease, is a chronic granuloma-
tous disease affecting mainly the skin and nerves caused by
Mycobacterium leprae. The course and clinical manifestations of the
disease are largely dependent on an individual’s immune response
to M. leprae and can be roughly classiﬁed into tuberculoid,
borderline, and lepromatous forms. It has long been known that
numerous clinical and serological similarities exist between pa-
tients with leprosy and connective tissue diseases. These varying
clinical manifestations, as well as a tendency of the disease to have
a protracted course, often lead to a delay in early recognition and
diagnostic confusion. We report a patient with borderline leprosy
who had initially been misdiagnosed for several years.Case report
A 40-year-old Myanmar-born man, living in Taiwan for 25 years,
presented to our hospital for acute appendicitis. During the
admission period, an in-patient dermatology consultation was
called to evaluate skin lesions and joint deformities. According to
the patient, he had suffered from bilateral hand and wrist pain,
swelling, and deformities for 4 years. Worsening ﬁngertip tingling,e no ﬁnancial or non-ﬁnancial
erials discussed in this article.
. Rd., Zhongshan Dist., Taipei
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).
iwanese Dermatological Associationumbness, and pallor, especially during cold weather, were noticed
around the same time. Decreased thermal sensation on the left
palm and ﬁngers ensued, which had resulted in burn injury several
times. He had received open carpal tunnel release surgery twice
4 years earlier, once at the elbow and the other time at the wrist,
but the symptoms still progressed. In addition, a malar rash was
observed at that time, which had become even worse after sun
exposure. Laboratory ﬁndings at that time showed positive anti-
nuclear antibody [ANA; 1:1280 (þ), speckled pattern] and positive
antiribonucleoprotein antibody (9.9 U/mL; normal value <5.0 U/
mL). He was previously diagnosed with systemic lupus erythema-
tosus (SLE) at a regional hospital 3 years earlier based on four of the
11 American Rheumatologic Association criteria for the diagnosis of
SLE (malar rash, photosensitivity, arthritis, positive ANA test).
Treatment with prednisolone 20 mg daily and hydroxychloroquine
200 mg daily were initiated, followed shortly by the addition of
cyclophosphamide 50 mg daily to control his disease. However, the
therapy did not control the symptoms, and skin lesions spread to
trunk and limbs in these 3 years. This patient had stopped using the
immunosuppressive agents 1 year before presentation.
On examination, the patient had generalized erythematous
annular patches and plaques with ill-deﬁned borders on the face,
trunk, and forelimbs (Figure 1). Hand swelling, muscle wasting,
claw deformity of ﬁngers, and drop hand were observed evidently
in the left hand (Figure 2). Neurologic examination at these areas
showed signiﬁcant sensory loss (touch, pain, and temperature
sensation) and muscle weakness.
Laboratory examination showed reduced hemoglobulin (94 g/L)
with increased reticulocyte production index (7.0%), a normal whiten. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 Generalized erythematous annular patches and plaques with ill-deﬁned borders on the (A) face and (B) back.
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elevated erythrocyte sedimentation rate (71 mm in the ﬁrst hour;
normal value <12 mm/hour). His autoimmune proﬁle revealed
seropositivity for ANA [1:160 (þ), speckled pattern], but other data
were within the normal limit, including complement fractions 3
and 4 (C3 and C4), antidouble strand DNA antibody, anticardiolipin
antibody screen, extractable nuclear antigen autoantibodies screen,
anti-Smith, antiribonucleoprotein, anti-Sjogren's syndrome A
antibody (anti-SSA), and anti-Sjogren's syndrome B antibody (anti-
SSB). This patient denied having other systemic disease, recent
travel history, smoking, or substance abuse. The initial impression
was subacute cutaneous lupus erythematous with a sensorimotor
polyneuropathy. A skin biopsy from the right forearm revealedFigure 2 Bilateral hand lesions of our patient: (A,B) Muscle wasting and clawdiffuse granulomatous inﬁltrate in the reticular dermis
(Figure 3A,B) composed of histiocytes, plasma cells, a few lym-
phocytes, and multinucleated giant cells. Some globi were also
noted in the granuloma. An acid fast stain showed an aggregate of
bacilli within the globi in keeping with lepromatous leprosy
(Figure 3C,D). The direct immunoﬂuorescence study was all nega-
tive. Slit-skin smears from bilateral forehead and earlobes showed
an average bacterial index of two. On nerve conduction studies, a
decrease in motor and sensory conduction velocity combined with
a prolonged motor distal latency and a decreased compound
muscle action potential were noted in the left ulnar and radial
nerve. These ﬁndings suggested sensorimotor polyneuropathy
superimposed with multiple entrapment neuropathies.deformity on the left hand; (C) erythematous swelling on the right hand.
Figure 3 (A) Diffuse granulomatous inﬁltrate in the reticular dermis [hematoxylin and eosin (H&E); original magniﬁcation, 40]. (B) Granulomatous inﬂammation in the reticular
dermis (H&E; original magniﬁcation, 100). (C) Globi were noted in the granulomas (H&E; original magniﬁcation, 400). (D) Aggregate of bacilli within the globi (acid fast stain;
original magniﬁcation, 1000).
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culoid leprosy including multiple asymmetrical annular inﬁltrated
plaques and early neuritis, he had many bacillary globi found his-
topathologically, which pointed towards lepromatous leprosy. The
average bacillary index from the skin smear of four sites was two,
which represents a low tomedium number of bacilli. Therefore, the
ﬁnal diagnosis was multibacillary borderline leprosy with derma-
tologic, neurologic, and rheumatic manifestations. Multidrug
therapy (MDT) with rifampicin 600 mg once a month, dapsone
100 mg daily, and clofazimine 300 mg once a month and 50 mg
daily was initiated. Skin rashes, joint pain, and hand swelling
improved greatly after the treatment. However, subjective left hand
numbness and muscle weakness persisted at the 1-year follow up.
Discussion
Our patient’s presentationwith peculiar skin rashes combined with
sensorimotor polyneuropathy and rheumatic manifestations, all
evolving over 3e4 years, led to the skin biopsy that conﬁrmed the
diagnosis of leprosy. Although the coexistence of SLE and leprosy
has been reported,1e3 SLE was not likely in this patient. First,
immunosuppressive agents were ineffective, including on the skin
and joint symptoms. Second, cutaneous manifestations gradually
improved after using MDT alone. Third, the autoantibody proﬁle,
complement level, and direct immunoﬂuorescence study result did
not give good support to the diagnosis of lupus. Leprosy has a
variable incubation period ranging from months to several years
and may progress slowly. Although the Myanmar man had left the
endemic area more than 25 years earlier, the disease may present
long afterwards. It is not clear when our patient acquired his
leprosy, but the most likely explanation is that his disease lay
dormant for many years.
Rheumatic manifestations, observed in as many as 64e77%
leprosy patients especially during reactional states,4,5 form thethird most prevalent complication after dermatologic and neuro-
logic abnormalities.6 In our patient, swollen hands syndrome,
arthritis, Raynaud’s phenomenon, and indurated facial rashes on
malar eminence were noted during the disease course. One
possible explanation for our patient having facial rashes reminis-
cent of malar rashes in lupus is that M. leprae grows best in cooler
areas of the human body. Hence, the skin lesions tend to be local-
ized to the chin, forehead, earlobes, and malar eminences.
It has been estimated that 6e75% of leprosy patients develop
arthritis at some stage of the disease.4,5,7e9 In a retrospective re-
view evaluating 1257 leprosy patients, Pereira et al found that the
predominant type of leprosy in the patients with arthritis was
lepromatous leprosy type (41.8%), followed by borderline tuber-
culoid type (23.6%), borderline (18.2%), and borderline lepromatous
type (16.4%).9 Also, the review showed that the most common type
of joint involvement was polyarticular, followed by oligoarticular
andmonoarticular. Thewrist, ankle, proximal interphalangeal joint,
and metacarpophalangeal joint were most frequently affected.9
Chauhan et al7 classify the arthritis in leprosy into the following
groups: (1) Charcot’s arthropathy secondary to peripheral sensory
neuropathy; (2) swollen hands and feet syndrome; (3) acute pol-
yarthritis of lepra reaction; and (4) chronic arthritis from direct
inﬁltration of the synovium by lepra bacilli. Since our patient had a
chronic course without a lepra reaction during diagnosis and
responded to MDT and nonsteroidal anti-inﬂammatory drugs, the
joint involvement in our patient seemed to be due to Charcot’s
arthropathy or chronic arthritis. Two commonly involved nerves in
Charcot’s arthropathy are the ulnar and median nerves.10 Early
changes associated with ulnar neuropathy are ﬂattening of the
hypothenar muscles and ultimately result in claw-hand deformity,
as observed in our patient.
Leprosy is invariably included in the list of diseases associated
with positive ANA tests. The presence of ANA has been reported to
vary from 3% to 34% usually in a low titer, and both speckled and
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probably reﬂects the heterogeneity of the sample, the duration, and
the type of the disease. Patients with a longer duration of illness, an
older age, multibacillary leprosy, and a history of repeated lepra
reaction attacks have been reported to predispose to ANA pro-
duction.13,15 Also, many other chronic infections such as malaria,
tuberculosis, and fungal infection often coexist with leprosy in
developing countries and they could augment the humoral im-
mune stimulation and increase the titer and range of autoanti-
bodies produced.13 It has been postulated that ANA presenting in
leprosy patients results fromweak cross-reactivity with complexed
nucleic acids and nucleoproteins exposed after cell destruction in
chronic inﬂammation. Newly exposed hidden antigens may pro-
vide antigenic determinants that stimulate adaptive immune
response and polyclonal B cell activation.15
In addition to ANA, many other serologic similarities exist be-
tween leprosy and autoimmune disease. Rheumatoid factor,16,17
antineutrophil cytoplasmic antibody,14,18,19 anticyclic citrullinated
peptide,16,17 and antiphospholipid antibodies20,21 have been re-
ported with varying incidences in different forms of leprosy. These
serology ﬁndings in conjunctionwith the rheumatic manifestations
described above may lead to misdiagnosis as rheumatic disorders.
Misdiagnosis often leads to years of corticosteroid or immuno-
suppressant administration, which probably modiﬁes the clinical
presentation of leprosy towards lepromatous forms.
Between 12% and 55% of new cases of leprosy have clinical signs
and symptoms of neuropathy at diagnosis.22 In the tuberculoid
pole, isolated damage of nerve trunks or more superﬁcial dermal
nerves occurs, while in the lepromatous pole, glove and stocking
sensory loss often take place. Granulomatous inﬂammation of pe-
ripheral nerves in leprosy causes nerve enlargement and impairs
sensory, motor, and autonomic function. Among them, numbness
and sensory loss occur earliest. As for sensory loss, temperature and
pain sensations generally decreased earlier than position and vi-
bration sense, and warmth perception is affected earlier than cold
perception.22 Motor function impairment, presenting later in the
disease course, results in muscle weakness and atrophy in the
distribution of involved peripheral nerves.23 As in our patient,
enlarged ulnar and median nerves are vulnerable to entrapment
and irritation behind the olecranon process and ﬂexor retinaculum,
respectively. They are usually the ﬁrst nerves to be compromised.
Sensory nerve conduction parameters, in particular amplitude, and
warm perception thresholds were by far the most sensitive mea-
sures for detecting neuropathy.22
Hansen’s disease is a great mimicker, and the diagnosis is
particularly challenging in patients in nonendemic regions and
with many rheumatic manifestations clinically and serologically.
Our case illustrates an unusual presentation of leprosy initially
diagnosed as SLE based on the diagnostic criteria. It is important to
recognize the potential association between rheumatic manifesta-
tions and leprosy, as delayed diagnosis and the use of immuno-
suppression in our patient probably led to a downgrading reaction,which usually causes irreversible nerve damage. We need to keep a
broad differential diagnosis in mind when assessing patients with
an undiagnosed granulomatous rash, even in the absence of any
history of recent prolonged stay in an endemic country until a
particular disease is proven. Diagnosis and initiation of therapy as
early as possible is necessary to prevent permanent nerve damage
and to reduce the risk of secondary transmission.
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